Abstract
Introduction
Osteoarthritis (OA) is a disease of the synovial joints and is the most common cause of chronic pain in the elderly. One of the treatment modalities for OA of the hip is viscosupplementation (VS). Today there are several different formulations of viscosupplements produced by different manufactures of different molecular weights. The objective of this review is to asses the efficacy of VS treatment of hip OA osteoarthritis in the current literature.
Material and methods
The following databases were searched: Medline (period 1966 to November 2006), Cochrane Database of Systematic Reviews (1988 to November 2006), Cochrane Clinical Trial Register (1988 to November 2006), Database of Abstracts on Reviews and Effectiveness, Current Controlled Trials, National Research Register and Embase (January 1988 to November 2006). The search terms [osteoarthritis, hip (joint), viscosupplementation, hyaluronic acid, hyaluronan, sodium hyaluronate and trade names] were applied to identify all studies relating to the use of VS therapy for OA of the hip joint.
Results
Sixteen articles concerning the efficacy of a total of 509 patients undergoing VS treatment for hip OA were included. Twelve European studies, three Turkish studies and one American study with Levels of Evidence ranging from I to IV evaluated the following products: Hylan G-F 20, Hyalgan®, Ostenil®, Durolane®, Fermatron® and Orthovisc®. Heterogeneity of included studies did not allow pooled analysis of data.
Discussion
Despite the relatively low Level of Evidence of the included studies, VS performed under fluoroscopic or ultrasound guidance seems an effective treatment and may be an alternative treatment of hip OA. Intra-articular injection of (derivatives of) HA into the hip joint appears to be safe and well tolerated. However, VS cannot be recommended as standard therapy in hip OA for wider populations, and therefore the indications remain a highly individualised matter.
Similar content being viewed by others
Abbreviations
- AAOS:
-
American Association Orthopaedic Surgeons
- CEBM:
-
Centre for Evidence Based Medicine
- HA:
-
Hyaluronic acid
- IA:
-
Intra-articular
- MDa:
-
Million Daltons
- MW:
-
Molecular weight
- NASHA:
-
Non-animal stabilised hyaluronic acid
- NSAID:
-
Non-steroidal anti inflammatory drug
- OA:
-
Osteo-arthritis
- PAS:
-
Pain analogue scale
- RCT:
-
Randomised controlled trial
- THA:
-
Total hip arthroplasty
- VAS:
-
Visual analogue scale
- VS:
-
Viscosupplementation
- WOMAC:
-
Western Ontario and McMaster Universities osteoarthritis index
- OMERACT:
-
Outcome measures in rheumatology
References
Adams ME (1993) Viscosupplementation: a treatment for osteoarthritis. J Rheum 20(suppl 39):2
American Academy of Orthopaedic Surgeons (AAOS), Council of Musculoskeletal Specialty Societies (COMSS) in Tarpon Springs, Florida, in April 1994
Balzas E (1982) The viscoelastic properties of synovial fluid and the special role of hyaluronic acid. In: Heflet A (ed) Disorders of the knee, 2nd edn. JB Lippencott, Philadelphia, pp 61–74
Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840
Bellamy N, Campbell J, Robinson V et al (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. In: The cochrane database of systematic reviews 19(2), Art No.: CD005321
Bellamy N, Kirwan J, Boers M et al (1997) Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 24(4):799–802
Berg P, Olsson U (2004) Intra articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study. Clin Exp Rheumatol 22:300–306
Bertolami C, Gay T, Clark G et al (1993) Use of sodium hyaluronate in treating temporo-mandibular joint disorders: a randomized double blind, placebo controlled clinical trial. J Oral Maxillofacial Surg 51:232–242
Bragantini A, Molinaroli F (1994) A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid. Clin Ther Res 55:3319–3330
Brocq O, Tran G, Breuil V et al (2002) Hip osteoarthritis: short term efficacy and safety of viscosupplementation by hylan G-F 20. An open label study in 22 patients. Joint Bone Spine 69(4):388–391
Caglar-Yagci H, Unsal S, Yagci I et al (2005) Safety and efficacy of ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip: a pilot study. Rheumatol Int 25(5):341–344
Chazerain P, Rolland D, Cordonnier C (1999) Septic hip arthritis after multiple injections into the joint of hyaluronate and glucocorticoid. Rev Rhum (Engl Ed) 6:436
Conrozier T, Bertin P, Mathieu P et al (2003) Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open label multicentre, pilot study. Clin Exp Rheumatol 21(5):605–610
Conrozier T, Vignon E (2005) Is there evidence to support the inclusion of viscosupplementation in the treatment paradigm for patients with hip osteoarthritis? Clin Exp Rheumatol 23:711–716
De Nies F, Fiddler MW (1997) Visual analog scale for the assessment of total hip arthroplasty. J Arthroplasty 12(4):416–419
Egsmose C, Lund B, Bach Andersen R (1984) Hip joint distension in osteoarthrosis. A triple-blind controlled study comparing the effect of intra-articular indoprofen with placebo. Scand J Rheumatol 13:238–242
Felson DT (1988) Epidemiology of hip and knee osteoarthritis. Epidemiol Rev 10:1–18
Fletcher B, Sackett DL (1979) Canadian task force on the periodic health examination: the Periodic Health Examination. CMAJ 121:1193–1254
Harris WH (1969) Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. J Bone Joint Surg Am 51-A:737–755
Hochberg MC, Altman RD, Brandt KD et al (1995) Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 38:1535–1540
Itokazu M, Matsunaga T (1995) Clinical evaluation of high molecular weight sodium hyaluronate for the treatment of patients with peri-arthritis of the shoulder. Clin Ther 17(5):946–955
Jadad AR, Moore A, Carroll D et al (1996) Assessing the quality of reports of randomised controlled trials: is blinding necessary? Contr Clin Trials 17:1–12
Kopp S, Akerman S, Nilner M et al (1991) Short term effects of intra-articular sodium hyaluronate, glucocorticoid, and saline injections on rheumatoid arthritis of the temporo-mandibular joint. J Craniomandibular Dis Facial oral Pain 5(4):231–238
Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799
Leardini G, Perbellini A, Franceschini M et al (1988) Intra-articular injections of hyaluronate acid in the treatment of the painful shoulder. Clin Ther 10:521–525
Lequesne M, Mery C, Samson M et al (1987) Indexes of severity for osteoarthritis of the hip and knee. Indexes of severity for osteoarthritis of the hip and knee. Validation and value in comparison with other assessment tests. Scand J Rheumatol Suppl 65:85–89
Ling SM, Bathon JM (1998) Osteoarthritis in older adults. J Am Geriatr Soc 46:216–225
Lo GH, LaValley M, McAlindon T et al (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis—a meta-analysis. JAMA 290(23):3115–3121
March LM, Bachmeier CJ (1997) Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 11:817–834
Marshall K (1997) The current status of hylan therapy for the treatment of osteoarthritis. Todays ther Trends 15:99–108
Migliore A, Martin LSM, Alimonte A (2003) Efficacy and safety of viscosupplementation by ultra-sound guided intra-articular injection in osteoarthritis of the hip. Osteoarthritis Cartil 11(4):305–306
Migliore A, Tormenta S, Massafra U et al (2005) Repeated ultrasound-guided intra-articular injections of 40 mg of Hyalgan may be useful in symptomatic relief of hip osteoarthritis. Osteoarthritis Cartil 13(12):1126–1127
Migliore A, Tormenta S, Martin LS et al (2005) Open pilot study of ultrasound guided intra-articular injection of Hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol 24(3):285–289
Migliore A, Tormenta S, Martin Martin LS et al (2006) The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol 25(3):389–393
Migliore A, Tormenta S, Martin Martin LS et al (2004) Safety profile of 185 ultrasound-guided intra-articular injections for treatment of rheumatic diseases of the hip. Reumatismo 56(2):104–109
Migliore A, Tormenta S, Massafra U et al (2006) 18 month observational study on efficacy of intraarticular hyaluronic acid (Hylan G-F 20) injections under ultrasound guidance in hip osteoarthritis. Reumatismo 58(1):39–49
Migliore A, Tormenta S, Valenta C et al (2005) Intra-articular treatment with hylan G-F 20 under ultrasound guidance in hip osteoarthritis. Clinical results after 12 months follow-up. Reumatismo 57(1):36–43
Pourbagher MA, Ozalay M, Pourbagher A (2005) Accuracy and outcome of sonographically guided intra-articular sodium hyaluronate injections in patients with osteoarthritis of the hip. J Ultrasound Med 24:1391–1395
Qvistgaard E, Christensen R, Torp-Pedersen S et al (2006) Intra-articular treatment of hip osteoarthritis: a randomised trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartil 14(2):163–170
Schulz KF, Chalmers I, Grimes DA et al (1994) Assessing the quality of randomisation from reports of controlled trials published in obstetrics and gynaecology journals. JAMA 272:125–128
Tepper S, Hochberg MC (1993) Factors associated with hip osteoarthritis: Data from the first National Health and Nutrition Examination Survey (NHANES-1). Am J Epidemiol 137:1081–1088
Thomas E, Peat G, Hill S et al (2004) The North Staffordshire Osteoarthritis Project-NorStop: prospective 3 year study of the epidemiology and management of clinical osteoarthritis in a general population of older adults. BMC Musculoskelet Disord 5:2
Tikiz C, Unlu Z, Sener A et al (2005) Comparison of the efficacy of lower and higher molecular weight viscosupplementation in treatment of hip osteoarthritis. Clin Rheumatol 24(3):244–250
Vad VB, Sakalkale D, Sculco TP et al (2003) Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil 84(8):1224–1226
van den Bekerom MPJ, Mylle G, Rys B et al (2006) Viscosupplementation in symptomatic severe hip-osteoarthritis: A review of the literature and report on 60 patients. Acta Orthop Belg 72:560–566
Verhagen AP, de Vet HC, de Bie RA et al (1998) Balneotherapy and quality assessment: interobserver reliability of the Maastricht criteria list and the need for blinded quality assessment. J Clin Epid 51:335–341
Weiss C, Band P (1995) Musculoskeletal applications of hyaluron and hylan. Potential uses in the foot and ankle. Clin Pod Med Surg 12(3):497–517
Acknowledgments
The authors are grateful to A. van Horssen for collecting the required articles and to N. Vandenhecke for her help in the preparation of this manuscript. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this review. No sources of funding were received to assist in this review. The authors have no conflicts of interest that are directly relevant to this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van den Bekerom, M.P.J., Lamme, B., Sermon, A. et al. What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg 128, 815–823 (2008). https://doi.org/10.1007/s00402-007-0447-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-007-0447-z